POSB51 A Cost-Effectivess Analysis of Trastuzumab Emtansine Versus Trastuzumab for the Adjuvant Treatment of Patients with Residual Invasive HER2-Positive Breast Cancer in Portugal
| Autor: | Silva Miguel, L, Pinheiro, B, Lopes, R, Revil, C, Monteiro, I, Borges, M |
|---|---|
| Zdroj: | In Value in Health January 2022 25(1) Supplement:S69-S70 |
| Databáze: | ScienceDirect |
| Externí odkaz: |
|
Full Text from ScienceDirect